What Women Need to Know: Understanding the FDA's New Guidance on Hormone Replacement Therapy (HRT)

Why the FDA Updated Its Position on HRT

The FDA's revised guidance reflects a recognition that the blanket fear surrounding hormone therapy, triggered by early Women's Health Initiative (WHI) results in 2002, left millions of symptomatic women undertreated. The update recalibrates risk communication while preserving appropriate caution for older initiators and long-duration users.

When the WHI estrogen-plus-progestin arm was halted early, headlines focused on a 26% relative increase in invasive breast cancer (hazard ratio 1.26, 95% CI 1.00 to 1.59) [1]. That statistic, while real, obscured absolute risk: roughly 8 additional breast cancer cases per 10,000 woman-years of use. Subsequent reanalysis published in JAMA showed that women aged 50 to 59 who initiated conjugated equine estrogens alone actually had a non-significant reduction in breast cancer incidence over 13 years of cumulative follow-up [2].

The FDA now acknowledges the "timing hypothesis" in its labeling language. Women who begin HRT within 10 years of menopause or before age 60 appear to derive cardiovascular benefit rather than harm. A 2015 Cochrane review of 19 trials (N=40,410) confirmed that hormone therapy started in early menopause reduced all-cause mortality (RR 0.70, 95% CI 0.52 to 0.95) and coronary heart disease events [3]. The agency stopped short of endorsing HRT for cardioprotection, but the softened labeling allows prescribers more clinical discretion.

Dr. Stephanie Faubion, medical director of the North American Menopause Society (NAMS), stated in the 2022 NAMS position statement: "For symptomatic women who are within 10 years of menopause onset and have no contraindications, the benefits of hormone therapy most likely outweigh the risks" [4]. The FDA's updated guidance aligns with this clinical consensus without formally adopting it as regulatory language.

What the FDA Now Approves and for Whom

The FDA approves systemic hormone therapy for three primary indications: treatment of moderate-to-severe vasomotor symptoms, prevention of postmenopausal osteoporosis (when other therapies are inappropriate), and treatment of moderate-to-severe vulvovaginal atrophy. The guidance does not expand approved indications but sharpens eligibility criteria.

Current FDA-approved formulations span multiple delivery routes. Oral options include conjugated estrogens (Premarin, 0.3 to 1.25 mg), estradiol (Estrace, 0.5 to 2 mg), and the combination product estradiol/norethindrone acetate (Activella). Transdermal patches such as Climara (estradiol 0.025 to 0.1 mg/day) and Vivelle-Dot offer steady-state delivery with a pharmacokinetic profile that bypasses first-pass hepatic metabolism [5]. This distinction matters clinically. A nested case-control study within the UK General Practice Research Database (N=80,396 cases) found that transdermal estradiol was not associated with increased venous thromboembolism risk (OR 0.96, 95% CI 0.78 to 1.18), while oral estrogen carried an OR of 1.44 (95% CI 1.27 to 1.63) [6].

For women with an intact uterus, concurrent progestogen is required with systemic estrogen to prevent endometrial hyperplasia. The FDA-approved options include medroxyprogesterone acetate (Provera), micronized progesterone (Prometrium, 100 to 200 mg), and the levonorgestrel-releasing intrauterine system (Mirena, used off-label for endometrial protection). Bijuva, a combination capsule containing 1 mg estradiol and 100 mg progesterone, received FDA approval in 2018 and represents the first oral bioidentical combination product with regulatory clearance [7].

The updated labeling now explicitly states that low-dose vaginal estrogen preparations (estradiol vaginal tablets 10 mcg, estradiol vaginal cream, or the estradiol vaginal ring Estring) for genitourinary syndrome of menopause do not require concurrent progestogen, even in women with an intact uterus. Systemic absorption at these doses is minimal [8].

The Compounding Pharmacy Question

The FDA's guidance draws a firm line between approved bioidentical products and compounded hormone preparations, warning that compounded formulations lack the safety, efficacy, and consistency data required of commercial drugs. This section of the guidance has generated the most public debate.

Compounded bioidentical hormones (cBHT), including estriol, bi-est (estriol/estradiol blends), and pellet implants, are prescribed by an estimated 1 to 2.5 million women in the United States [9]. The National Academies of Sciences, Engineering, and Medicine (NASEM) published a 2020 report concluding that cBHT products present "patient safety concerns related to variable quality and potency" and that "there is no evidence that cBHT preparations are safer or more effective than FDA-approved hormone therapies" [10].

The FDA's 2025 draft guidance proposes that compounding pharmacies producing large volumes of hormone preparations register under Section 503B of the Federal Food, Drug, and Cosmetic Act, which subjects them to current Good Manufacturing Practice (cGMP) requirements. Pharmacies operating under 503A (traditional patient-specific compounding) would still be exempt from cGMP but face tighter state-level reporting.

Dr. JoAnn Manson, principal investigator of the WHI and professor at Harvard Medical School, wrote in the New England Journal of Medicine: "The assumption that compounded hormones are natural and therefore safer is not supported by evidence, and may divert women from therapies with established benefit-risk profiles" [11]. The FDA guidance echoes this concern without banning compounding outright. It instead pushes for transparency, requiring pharmacies to disclose that their products are not FDA-approved and have not undergone the same testing as commercial alternatives.

Pellet implants, a particularly popular compounded format, present unique risks. Supraphysiologic estradiol levels exceeding 300 pg/mL are common after pellet insertion, and the FDA has received adverse event reports of endometrial hyperplasia and erythrocytosis linked to testosterone pellets in women [9]. The guidance specifically flags pellet therapy as an area requiring additional clinical scrutiny.

Reassessing Risk: Breast Cancer, Cardiovascular Disease, and Cognition

The updated guidance reflects a more granular understanding of HRT-related risks, moving beyond the one-size-fits-all warnings that dominated post-WHI prescribing. Risk varies by formulation, route of delivery, type of progestogen, timing of initiation, and individual patient factors.

On breast cancer, the WHI estrogen-alone arm (conjugated equine estrogens without progestin in women with prior hysterectomy) showed a hazard ratio of 0.77 (95% CI 0.59 to 1.01) for invasive breast cancer over 7.2 years of intervention, with continued reduction through 20 years of cumulative follow-up [2]. The combined estrogen-plus-progestin arm showed increased risk beginning after approximately 3 to 5 years. The type of progestogen may matter: a French E3N cohort study (N=80,377) found that micronized progesterone combined with estradiol did not significantly increase breast cancer risk (RR 1.00, 95% CI 0.83 to 1.22 for up to 5 years of use), while synthetic progestins did (RR 1.69, 95% CI 1.50 to 1.91) [12].

Regarding cardiovascular outcomes, the timing hypothesis has gained enough traction that the 2022 Endocrine Society clinical practice guideline recommends: "For women with menopausal symptoms who are within 10 years of menopause onset or younger than age 60 and have no contraindications, we suggest menopausal hormone therapy" [13]. The FDA labeling retains the black-box warning for stroke and venous thromboembolism but acknowledges that absolute risk is low in younger, recently menopausal women.

The cognitive domain remains uncertain. The WHI Memory Study (WHIMS), which enrolled women aged 65 to 79, showed increased dementia risk with combined HRT. But the ELITE trial and KEEPS trial, which enrolled younger women (mean age 52 to 55), showed no cognitive harm and some trends toward benefit in verbal memory [14]. The FDA guidance does not approve HRT for cognitive protection but no longer implies uniform cognitive risk across all age groups.

Practical Prescribing Under the New Guidance

For clinicians, the FDA's update translates into a decision framework that weighs symptom severity, time since menopause, cardiovascular risk profile, breast cancer history, and patient preference. The lowest effective dose for the shortest duration consistent with treatment goals remains the prescribing standard.

Starting doses for newly symptomatic women typically begin at the lower end of available formulations: 0.5 mg oral estradiol, 0.025 to 0.0375 mg/day transdermal estradiol, or 0.3 mg conjugated estrogens. If vasomotor symptoms are not adequately controlled at 4 to 8 weeks, dose escalation is appropriate. The FDA's labeling now recommends annual reassessment with a shared decision-making conversation about continuation [5].

For women who cannot or prefer not to use hormones, the FDA has approved non-hormonal alternatives. Fezolinetant (Veozah), a neurokinin 3 receptor antagonist, received FDA approval in 2023 for moderate-to-severe vasomotor symptoms. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 60.1% at week 12 compared with 42.6% for placebo [15]. Paroxetine mesylate (Brisdelle, 7.5 mg) remains the only SSRI FDA-approved for hot flashes.

The guidance also addresses duration. While the "shortest duration" principle persists, the FDA acknowledges that some women require therapy for years or even indefinitely. Abrupt discontinuation can trigger symptom rebound. A gradual taper, reducing dose by 50% every 3 to 6 months with symptom monitoring, is the preferred approach per NAMS and ACOG recommendations [4].

Women with premature ovarian insufficiency (POI, menopause before age 40) represent a special population. The FDA guidance recognizes that these women face increased risks of osteoporosis, cardiovascular disease, and cognitive decline without hormone replacement, and it supports continuation of HRT at least until the median age of natural menopause (approximately 51 years) [13].

What the Guidance Does Not Address

Several gaps remain in the FDA's updated framework. The agency does not provide specific guidance on testosterone therapy for women, despite growing evidence supporting low-dose testosterone for hypoactive sexual desire disorder. The Global Consensus Position Statement on testosterone therapy for women, endorsed by multiple international societies, recommends testosterone for postmenopausal women with HSDD after excluding other causes [16]. No testosterone product is currently FDA-approved for women in the United States.

The guidance also does not resolve the regulatory ambiguity around estriol. Estriol, a weaker estrogen commonly used in compounded preparations, is classified by the FDA as a bulk drug substance that may be used in compounding under 503A. Yet no estriol-containing product has received FDA approval, and the evidence base for its efficacy in vasomotor symptoms is thin compared with estradiol.

Long-term outcome data beyond 15 to 20 years of use remain sparse. The WHI post-intervention follow-up provides the longest dataset, but participants were older at enrollment than the population now being targeted for early initiation. Ongoing observational studies and registries will be needed to fill this evidence gap.

Women taking HRT should have baseline mammography, blood pressure measurement, and lipid assessment before initiation, with annual follow-up including breast examination and individualized screening per USPSTF recommendations [17].